FY2026 Earnings Estimate for BioSyent Issued By Bloom Burton

BioSyent Inc. (CVE:RX - Free Report) - Research analysts at Bloom Burton decreased their FY2026 earnings per share (EPS) estimates for BioSyent in a report issued on Monday, March 17th. Bloom Burton analyst D. Martin now forecasts that the company will post earnings of $0.88 per share for the year, down from their prior estimate of $0.91. The consensus estimate for BioSyent's current full-year earnings is $0.69 per share.

BioSyent Price Performance

RX traded up C$0.05 during midday trading on Wednesday, hitting C$11.30. 3,440 shares of the company traded hands, compared to its average volume of 4,553. The company has a market capitalization of C$129.24 million, a price-to-earnings ratio of 18.34 and a beta of 0.93. The business has a 50 day simple moving average of C$11.03 and a two-hundred day simple moving average of C$11.12. The company has a current ratio of 3.92, a quick ratio of 6.91 and a debt-to-equity ratio of 2.90. BioSyent has a 52-week low of C$8.24 and a 52-week high of C$12.13.

Insider Transactions at BioSyent

In other BioSyent news, insider FAX Capital Corp. sold 112,400 shares of the business's stock in a transaction on Monday, December 23rd. The stock was sold at an average price of C$11.28, for a total transaction of C$1,267,557.28. Insiders sold 112,540 shares of company stock valued at $1,269,132 over the last 90 days. 33.65% of the stock is currently owned by corporate insiders.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.

Remove Ads